Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Quantum Biopharma Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
Research and development
0
7.83
6.33
6.91
Selling and marketing
0.62
Operating income
-22.5
-30.7
-33.7
-27.4
Interest expense
0.16
0.24
0.07
0.05
Income from continuing operations
-34.1
-28.5
-33.9
-26.7
Net income to minority interests
-35.3
-23.6
Net income
-39.1
-31.8
-35.3
-23.6
EBITDA
-20.5
-26.8
-29.7
-22.9
Balance sheet
FY2020
FY2020
FY2021
FY2022
Cash and equivalents
5.97
17.5
35.3
17
Short-term investments
0
0.16
0
Receivables
1.56
0.16
0.5
0.37
Inventory
0.71
0
Total current assets
8.56
26.9
45.9
17.9
Property, plant and equipment
8.88
0
0
0.11
Lease right-of-use assets
0.1
0
0.17
0.16
Intangible assets
16.8
13.4
16.2
12
Total assets
43.2
42
63
38.4
Accounts payable
3.36
3.7
7.51
7.11
Total current liabilities
6.83
5.58
8.7
7.83
Lease liabilities
0.11
0.08
0.13
0.04
Total liabilities
6.94
5.66
8.83
7.87
Paid-in capital
17.4
18.8
22.6
28.5
Retained earnings
-59.1
-90.9
-126
-144
Shareholders' equity
30.5
Minority interests
0
Total equity
36.3
36.3
54.1
30.5
Total liabilities and equity
43.2
42
63
38.4
Cash flow statement
FY2020
FY2020
FY2021
FY2022
Net income
-39.1
-31.8
-35.3
-23.6
Depreciation and amortization
1.94
3.9
4.05
4.54
Cash from operations
-13.7
-19.1
-20.7
-28.3
Capital expenditures
0
0
-0.11
Cash from investing
-0.23
6.51
0.27
12.1
Stock issued
3.43
25.1
38.3
0
Cash from financing
4.01
24.2
38.2
-2.07
Net change in cash
-9.93
11.6
17.7
-18.3
Free cash flow
-19.1
-20.7
-28.4
Key metrics
Worked out from the statements above. Latest values use fiscal 2022. Valuation uses the share price of $3.85 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-77.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-46.6%
Net income / average total assets.
Return on invested capital (ROIC)
-159.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-39.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-3.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.28x
Current assets / current liabilities.
Quick ratio
2.22x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.17x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/B
1.02x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.68x
Market cap / tangible book value, when positive.
FCF yield
-91.4%
Free cash flow / market cap.
Earnings yield
-75.8%
Net income / market cap (the inverse of P/E).
Was Quantum Biopharma Ltd. profitable in fiscal 2022?
No. It reported a net loss of $23.6M.
How much free cash flow did Quantum Biopharma Ltd. generate in fiscal 2022?
Cash from operations of $28.3M minus capital expenditures of $114.0K left free cash flow of -$28.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.